Members of the board of directors and management subscribe in ongoing rights issue
Biosergen AB (publ) (“Biosergen” or the “Company”) announce that members of the board of directors, through affiliated companies, management team and employees subscribe for 6,563,092 units, corresponding to SEK 15.8 million in the ongoing rights issue of units (the “Rights Issue”).
Subscriptions from the board of directors and management team
The largest shareholder Östersjöstiftelsen, represented by board member Mattias Klintemar, subscribes for 5,625,000 units, corresponding to SEK 13.5 million in accordance with previously communicated subscription commitment. In addition, the second largest shareholder Rosetta Capital Ltd., represented by Biosergen’s chairman of the board, Torsten Goesch, subscribes for 666,666 units, corresponding to SEK 1.6 million. Other representatives from the board of directors, management team and employees subscribe for a total of 271,426 units, corresponding to approximately SEK 650 thousand.
Together, the board of directors, members from the management team and employees subscribe for 6,563,092 units, corresponding to SEK 15.8 million in the Rights Issue. The subscriptions correspond to 38.8 percent of the Rights Issue.
Subscription and underwriting commitments
The Rights Issue is covered to approximately 42.3 percent, corresponding to approximately SEK 17.2 million through subscription commitments from existing shareholders, including Biosergen’s largest shareholder Östersjöstiftelsen.
In addition to the subscription commitments, existing shareholders have entered into underwriting commitments of SEK 9.2 million corresponding to approximately 22.7 percent of the Rights Issue. Thus, the Rights Issue is covered to 65 percent by subscription commitments and underwriting commitments.
Shareholder letter available on website
For information on how to subscribe in the Rights Issue and a few summarizing words from CEO Tine Kold Olesen, please see the shareholder letter published on www.biosergen.net or https://emission.mangold.se/.
Advisors
Mangold Fondkommission AB is the financial advisor to Biosergen in connection with the Rights Issue. Advokatfirman Hammarskiöld & Co AB is the legal advisor to the Company in connection with the Rights Issue.
For further information about Biosergen, please contact:
Tine Olesen, CEO
Telephone: +45 3135 5707
E-mail: tine.olesen@biosergen.net
Niels Lauren, CFO
Telephone: +45 4014 5059
E-mail: niels.laursen@biosergen.net
The Company’s Certified Adviser is Carnegie Investment Bank AB (publ).
About Biosergen
Biosergen is a biotechnology company in the clinical stage within the therapeutic field of life-threatening fungal diseases. Biosergen’ s mission is to develop the drug candidate BSG005, into a new first line treatment choice for resistant and/or difficult to treat invasive fungal infections, to save thousands of lives of immune-compromised cancer- transplant- and AIDS patients every year.